All Health Articles
Mirvetuximab Soravtansine-Gynx - Targeting Hope in FRα Positive, Platinum-Resistant Cancers
Mirvetuximab soravtansine-gynx is a targeted therapy for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
8 min readMay 7, 2024
